Literature DB >> 35606559

Expanding the search for small-molecule antibacterials by multidimensional profiling.

Karin Ortmayr1, Roberto de la Cruz Moreno1, Mattia Zampieri2.   

Abstract

New techniques for systematic profiling of small-molecule effects can enhance traditional growth inhibition screens for antibiotic discovery and change how we search for new antibacterial agents. Computational models that integrate physicochemical compound properties with their phenotypic and molecular downstream effects can not only predict efficacy of molecules yet to be tested, but also reveal unprecedented insights on compound modes of action (MoAs). The unbiased characterization of compounds that themselves are not growth inhibitory but exhibit diverse MoAs, can expand antibacterial strategies beyond direct inhibition of core essential functions. Early and systematic functional annotation of compound libraries thus paves the way to new models in the selection of lead antimicrobial compounds. In this Review, we discuss how multidimensional small-molecule profiling and the ever-increasing computing power are accelerating the discovery of unconventional antibacterials capable of bypassing resistance and exploiting synergies with established antibacterial treatments and with protective host mechanisms.
© 2022. Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35606559     DOI: 10.1038/s41589-022-01040-4

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   16.174


  79 in total

1.  Essentiality of DevR/DosR interaction with SigA for the dormancy survival program in Mycobacterium tuberculosis.

Authors:  Uma S Gautam; Kriti Sikri; Atul Vashist; Varshneya Singh; Jaya S Tyagi
Journal:  J Bacteriol       Date:  2013-12-06       Impact factor: 3.490

2.  Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.

Authors:  Dean G Brown; Tricia L May-Dracka; Moriah M Gagnon; Ruben Tommasi
Journal:  J Med Chem       Date:  2014-12-02       Impact factor: 7.446

3.  A Common Platform for Antibiotic Dereplication and Adjuvant Discovery.

Authors:  Georgina Cox; Arthur Sieron; Andrew M King; Gianfranco De Pascale; Andrew C Pawlowski; Kalinka Koteva; Gerard D Wright
Journal:  Cell Chem Biol       Date:  2016-12-22       Impact factor: 8.116

4.  Predictive compound accumulation rules yield a broad-spectrum antibiotic.

Authors:  Michelle F Richter; Bryon S Drown; Andrew P Riley; Alfredo Garcia; Tomohiro Shirai; Riley L Svec; Paul J Hergenrother
Journal:  Nature       Date:  2017-05-10       Impact factor: 49.962

5.  Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes.

Authors:  Eachan O Johnson; Emily LaVerriere; Emma Office; Mary Stanley; Elisabeth Meyer; Tomohiko Kawate; James E Gomez; Rebecca E Audette; Nirmalya Bandyopadhyay; Natalia Betancourt; Kayla Delano; Israel Da Silva; Joshua Davis; Christina Gallo; Michelle Gardner; Aaron J Golas; Kristine M Guinn; Sofia Kennedy; Rebecca Korn; Jennifer A McConnell; Caitlin E Moss; Kenan C Murphy; Raymond M Nietupski; Kadamba G Papavinasasundaram; Jessica T Pinkham; Paula A Pino; Megan K Proulx; Nadine Ruecker; Naomi Song; Matthew Thompson; Carolina Trujillo; Shoko Wakabayashi; Joshua B Wallach; Christopher Watson; Thomas R Ioerger; Eric S Lander; Brian K Hubbard; Michael H Serrano-Wu; Sabine Ehrt; Michael Fitzgerald; Eric J Rubin; Christopher M Sassetti; Dirk Schnappinger; Deborah T Hung
Journal:  Nature       Date:  2019-06-19       Impact factor: 49.962

6.  Optimized arylomycins are a new class of Gram-negative antibiotics.

Authors:  Peter A Smith; Michael F T Koehler; Hany S Girgis; Donghong Yan; Yongsheng Chen; Yuan Chen; James J Crawford; Matthew R Durk; Robert I Higuchi; Jing Kang; Jeremy Murray; Prasuna Paraselli; Summer Park; Wilson Phung; John G Quinn; Tucker C Roberts; Lionel Rougé; Jacob B Schwarz; Elizabeth Skippington; John Wai; Min Xu; Zhiyong Yu; Hua Zhang; Man-Wah Tan; Christopher E Heise
Journal:  Nature       Date:  2018-09-12       Impact factor: 49.962

7.  Identification of antibiotic pairs that evade concurrent resistance via a retrospective analysis of antimicrobial susceptibility test results.

Authors:  Andrew M Beckley; Erik S Wright
Journal:  Lancet Microbe       Date:  2021-07-23

8.  Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.

Authors:  Jonah Larkins-Ford; Talia Greenstein; Nhi Van; Yonatan N Degefu; Michaela C Olson; Artem Sokolov; Bree B Aldridge
Journal:  Cell Syst       Date:  2021-08-31       Impact factor: 10.304

9.  A Deep Learning Approach to Antibiotic Discovery.

Authors:  Jonathan M Stokes; Kevin Yang; Kyle Swanson; Wengong Jin; Andres Cubillos-Ruiz; Nina M Donghia; Craig R MacNair; Shawn French; Lindsey A Carfrae; Zohar Bloom-Ackermann; Victoria M Tran; Anush Chiappino-Pepe; Ahmed H Badran; Ian W Andrews; Emma J Chory; George M Church; Eric D Brown; Tommi S Jaakkola; Regina Barzilay; James J Collins
Journal:  Cell       Date:  2020-02-20       Impact factor: 41.582

10.  Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.

Authors:  Barbara Bosch; Michael A DeJesus; Nicholas C Poulton; Wenzhu Zhang; Curtis A Engelhart; Anisha Zaveri; Sophie Lavalette; Nadine Ruecker; Carolina Trujillo; Joshua B Wallach; Shuqi Li; Sabine Ehrt; Brian T Chait; Dirk Schnappinger; Jeremy M Rock
Journal:  Cell       Date:  2021-07-22       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.